Cysteine proteases as disease markers

Clinica Chimica Acta

Volumn 342, Issue 1-2, 2004, Pages 41-69

  Berdowska, Izabela ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Arthritis; Cancer; Cysteine cathepsins; Diagnostic markers; Periodontitis; Prognostic markers

Indexed keywords

CATHEPSIN B; CATHEPSIN F; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN O; CATHEPSIN S; CATHEPSIN V; CATHEPSIN W; CATHEPSIN X; CYSTEINE CATHEPSIN DERIVATIVE; CYSTEINE DERIVATIVE; CYSTEINE PROTEINASE; DIPEPTIDYL PEPTIDASE I; ENZYME PRECURSOR; HORMONE PRECURSOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PAPAIN; PEPTIDASE; PROTEIN PRECURSOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; APOPTOSIS; BONE REMODELING; BRAIN TUMOR; BREAST TUMOR; CELL CYCLE; CELL DIFFERENTIATION; DISEASE MARKER; ENZYME ACTIVATION; GASTROINTESTINAL TUMOR; GENE MUTATION; GENETIC DISORDER; HAIM MUNK SYNDROME; HAIR FOLLICLE; HEAD AND NECK CANCER; HORMONE ACTION; HUMAN; INFLAMMATORY DISEASE; KERATINOCYTE; KERATOSIS PALMOPLANTARIS; LUNG TUMOR; MELANOMA; MYOSITIS; OSTEOARTHRITIS; PERIODONTITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PYKNODYSOSTOSIS; REPRODUCTION; REVIEW; RHEUMATOID ARTHRITIS; UPREGULATION;

CYSTEINE ENDOPEPTIDASES; DIAGNOSIS; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 1542604677     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.12.016     Document Type: Review

References (248)

1. Rawlings ND, Barrett AJ, MEROPS - The Peptidase Database. Release 6.30 http://merops.sanger.ac.uk/2003.
2. Barrett A.J., Rawlings N.D. Evolutionary lines of cysteine peptidases. Biol. Chem. 382:2001;727-733.
3. Turk B., Turk V., Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 378:1997;141-150.
4. Dolenc I., Turk B., Pungercic G., Ritonja A., Turk V. Oligomeric structure and substrate induced inhibiton of human cathepsin C. J. Biol. Chem. 270:1995;21626-21631.
5. Wex T., Buhling F., Wex H.et al. Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum. J. Immunol. 167:2001;2172-2178.
6. Dunn A.D., Crutchfield H.E., Dunn J.T. Thyroglobulin processing by thyroidal proteases. J. Biol. Chem. 266:1991;20198-20204.
7. Brix K., Lemansky P., Herzog V. Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology. 137:1996;1963-1974.
8. Friedrichs B., Tepel C., Reinheckel T.et al. Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest. 111:2003;1733-1745.
9. Okamura-Oho Y., Zhang S., Callahan J.W., Murata M., Oshima A., Suzuki Y. Maturation anid degradation of β-galactosidase in the post-Golgi compartment are regulated by cathepsin B and a non-cysteine protease. FEBS Lett. 419:1997;231-234.
10. Jutras I., Reudelhuber T.L. Prorenin processing by cathepsin B in vitro and in transfected cells. FEBS Lett. 443:1999;48-52.
11. Halangk W., Lerch M.M., Brandt-Nedelev B.et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J. Clin. Invest. 106:2000;773-781.
12. Pham C.T., Ley T.J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:1999;8627-8632.
13. Adkison A.M., Raptis S.Z., Kelley D.G., Pham C.T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J. Clin. Invest. 109:2002;363-371.
14. Brasch F., ten Brinke A., Johnen G.et al. Involvement of cathepsin H in the processing of the hydrophobic surfactant-associated protein C in type II pneumocytes. Am. J. Respir. Cell Mol. Biol. 26:2002;659-670.
15. Dickinson D.P. Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit. Rev. Oral. Biol. Med. 13:2002;238-275.
16. Driessen C., Lennon-Dumenil A.M., Ploegh H.L. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcgamma receptors. Eur. J. Immunol. 31:2001;1592-1601.
17. Wiendl H., Lautwein A., Mitsdorffer M.et al. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J. Neuroimmunol. 138:2003;132-143.
18. + T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J. Exp. Med. 195:2002;1349-1358.
19. Deussing J., Roth W., Saftig P., Peters C., Ploegh H.L., Villadangos J.A. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4516-4521.
20. Chapman H.A., Riese R.J., Shi G.P. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 59:1997;63-88.
21. Riese R.J., Wolf P.R., Bromme D.et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 4:1996;357-366.
22. Wolters P.J., Chapman H.A. Importance of lysosomal cysteine proteases in lung disease. Respir. Res. 1:2000;170-177.
23. Shi G.P., Villadangos J.A., Dranoff G.et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 10:1999;197-206.
24. Riese R.J., Mitchell R.N., Villadangos J.A.et al. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 101:1998;2351-2363.
25. Driessen C., Bryant R.A., Lennon-Dumenil A.M.et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 147:1999;775-790.
26. Pluger E.B., Boes M., Alfonso C.et al. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur. J. Immunol. 32:2002;467-476.
27. Villadangos J.A., Bryant R.A., Deussing J.et al. Proteases involved in MHC class II antigen presentation. Immunol. Rev. 172:1999;109-120.
28. Maurer D., Fiebiger E., Reininger B.et al. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J. Immunol. 161:1998;2731-2739.
29. Nakagawa T.Y., Brissette W.H., Lira P.D.et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 10:1999;207-217.
30. Beers C., Honey K., Fink S., Forbush K., Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon γ-treated macrophages. J. Exp. Med. 197:2003;169-179.
31. Schmid H., Sauerbrei R., Schwarz G., Weber E., Kalbacher H., Driessen Ch. Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/macrophages. Biol. Chem. 383:2002;1277-1283.
32. Schwarz G., Boehncke W.H., Braun M.et al. Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. J. Invest. Dermatol. 119:2002;44-49.
33. Shi G.P., Bryant R.A., Riese R.et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J. Exp. Med. 91:2000;1177-1186.
34. Nakagawa T., Roth W., Wong P.et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 280:1998;450-453.
35. Benavides F., Giordano M., Fiette L.et al. Nackt (nkt), a new hair loss mutation of the mouse with associated CD4 deficiency. Immunogenetics. 49:1999;413-419.
36. Bromme D., Kaleta J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. 8:2002;1639-1658.
37. Greiner A., Lautwein A., Overkleeft H.S., Weber E., Driessen C. Activity and subcellular distribution of cathepsins in primary human monocytes. J. Leukoc. Biol. 73:2003;235-242.
38. Lautwein A., Burster T., Lennon-Dumenii A.-M.et al. Inflammatory stimuli recruit cathepsin activity to late endosomal compartments in human dendritic cells. Eur. J. Immunol. 32:2002;3348-3357.
39. Zavasnik-Bergant V., Sekirnik A., Golouh R., Turk V., Kos J. Immunochemical localisation of cathepsin S, Cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue. Biol. Chem. 382:2001;799-804.
40. Delaisse J.-M., Engsig M.T., Everts V.et al. Proteinases in bone resorption: obvious and less obvious roles. Clin. Chim. Acta. 291:2000;223-234.
41. Saftig P., Hunziker E., Wehmeyer O.et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13453-13458.
42. Leung-Toung R., Li W., Tam T.F., Karimian K. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. 9:2002 (May);979-1002.
43. Roth W., Deussing J., Botchkarev V.A.et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J. 14:2000;2075-2086.
44. Benavides F., Starost M.F., Flores M., Gimenez-Conti I.B., Guenet J.-L., Conti C.J. Impaired hair follicle morphogenesis and cycling with abnormal epidermal differentiation in nackt mice, a cathepsin L-deficient mutation. Am. J. Pathol. 161:2002;693-703.
45. Benavides F., Venable A., Poetschke Klug H.et al. The CD4 T cell deficient mouse mutation Nackt (nkt) involves a deletion in the cathepsin L gene (Ctsl). Immunogenetics. 53:2001;233-242.
46. Tobin D.J., Foitzik K., Reinheckel T.et al. The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am. J. Pathol. 160:2002;1807-1821.
47. Reinheckel T., Deussing J., Roth W., Peters C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem. 382:2001;735-741.
48. Wright W.W., Smith L., Kerr C., Charron M. Mice that express enzymatically inactive cathepsin L exhibit abnormal spermatogenesis. Biol. Reprod. 68:2003;680-687.
49. Zabludoff S.D., Charron M., DeCerbo J.N., Simukova N., Wright W.W. Male germ cells regulate transcription of the cathepsin L gene by rat Sertoli cells. Endocrinology. 142:2001;2318-2327.
50. Wright W.W. Germ cell-Sertoli cell interactions: analysis of the biosynthesis and secretion of cyclic protein-2. Dev. Biol. 130:1988;45-56.
51. Zabludoff S., Erickson-Lawrence M., Wright W. Sertoli cells, proximal convoluted tubules in the kidney and neurons in the brain contain cyclic protein-2. Biol. Reprod. 43:1990;15-24.
52. Wong C.C., Chung S.S., Grima J.et al. Changes in the expression of junctional and nonjunctional complex component genes when inter-Sertoli tight junctions are formed in vitro. J. Androl. 21:2000;227-237.
53. Robker R.L., Russell D.L., Espey L.L., Lydon J.P., O'Malley B.W., Richards J.S. Progesterone-regulated genes in the ovulation process: ADAMTS-1 and cathepsin L proteases. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4689-4694.
54. Sol-Church K., Shipley J., Beckman D.A., Mason R.W. Expression of cysteine proteases in extraembryonic tissues during mouse embryogenesis. Arch. Biochem. Biophys. 372:1999;375-381.
55. Afonso S., Romagnano L., Babiarz B. The expression and function of cystatin C and cathepsin B and cathepsin L during mouse embryo implantation and placentation. Development. 124:1997;3415-3425.
56. Turk B., Stoka V., Rozman-Pungercar J.et al. Apoptotic pathways: involvement of lysosomal proteases. Biol. Chem. 383:2002;1035-1044.
57. Guicciardi M.E., Miyoshi H., Bronk S.F., Gores G.J. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am. J. Pathol. 159:2001;2045-2054.
58. Foghsgaard L., Lademann U., Wissing D., Poulsen B., Jaattela M. Cathepsin B mediates tumor necrosis factor-induced arachidonic acid release in tumor cells. J. Biol. Chem. 277:2002;39499-39506.
59. Roberts L.R., Kurosawa H., Bronk S.F.et al. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology. 113:1997;1714-1726.
60. Yamashima T., Kohda Y., Tsuchiya K.et al. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'. Eur. J. Neurosci. 10:1998;1723-1733.
61. Felbor U., Kessler B., Mothes W.et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. PNAS. 99:2002;7883-7888.
62. Shi G.-P., Sukhova G.K., Kuzuya M.et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92:2003;493-500.
63. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta. 291:2000;113-135.
64. Yan S., Sameni M., Sloane B.F. Cathepsin B and human tumor progression. Biol. Chem. 379:1998;113-123.
65. Kos J., Werle B., Lah T., Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers. 15:2000;84-89.
66. Lah T.T., Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379:1998;125-130.
67. Szpaderska A., Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res. 61:2001;3493-3500.
68. Sever N., Filipic M., Brzin J., Lah T.T. Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro. Biol. Chem. 383:2002;839-842.
69. Coulibaly S., Schwihla H., Abrahamson M.et al. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int. J. Cancer. 83:1999;526-531.
70. Krueger S., Haeckel C., Buehling F., Roessner A. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res. 59:1999;6010-6014.
71. Van Noorden C.J.F., Jonges T.G.N., Van Marle J.et al. Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin. Exp. Metastasis. 16:1998;159-167.
72. Kirschke H., Eerola R., Hopsu-Havu V.K., Bromme D., Vuorio E. Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur. J. Cancer. 36:2000;787-795.
73. Frade R., Rodrigues-Lima F., Huang S., Xie K., Guillaume N., Bar-Eli M. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 58:1998;2733-2736.
74. Sinha AA, Gleason DF, Staley NA, Wilson MJ, Sameni M, Sloane BF, Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anatom. Rec. 995(241):353-362.
75. Mai J., Sameni M., Mikkelsen T., Sloane B.F. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 383:2002;1407-1413.
76. Santamaria I., Velasco G., Cazorla M., Fueyo A., Campo E., López-Otín C. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58:1998;1624-1630.
77. Yano M., Hirai K., Naito Z.et al. Expression of cathepsin B and cystatin C in human breast cancer. Surg. Today. 31:2001;385-389.
78. Lah T.T., Kokalj-Kunovar M., Drobnic-Kosorok M.et al. Cystatins and cathepsins in breast carcinoma. Biol. Chem. Hoppe-Seyler. 373:1992;595-604.
79. Lah T.T., Kokalj-Kunovar M., Strukelj B.et al. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer. 50:1992;36-44.
80. Gabrijelcic D., Svetic B., Spaic D., Skrk J., Budihna M., Turk V. Determination of cathepsins B, H, L and kininogen in breast cancer patients. AAS, Recent Prog. Kinins. 38/II:1992;350-357.
81. Lah T.T., Calaf G., Kalman E.et al. Cathepsins, D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC). Biol. Chem. Hoppe-Seyler. 376:1995;357-363.
82. Gabrijelcic D., Svetic B., Spaic D.et al. Cathepsins, B, H and L in human breast carcinoma. Eur. J. Clin. Chem. Clin. Biochem. 30:1992;69-74.
83. Maguire T.M., Shering S.G., Duggan C.M., McDermott E.W., O'Higgins N.J., Duffy M.J. High levels of cathepsin B predict poor outcome in patients with breast cancer. Int. J. Biol. Markers. 13:1998;139-144.
84. Bervar A., Zajc I., Sever N., Katunuma N., Sloane B.F., Lah T.T. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol. Chem. 384:2003;447-455.
85. Premzl A., Zavasnik-Bergant V., Turk V., Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. 283:2003;206-214.
86. Premzl A., Puizdar V., Zavasnik-Bergant V.et al. Invasion of ras-transformed breast epithelial cells depends on the proteolytic activity of cysteine and aspartic proteinases. Biol. Chem. 382:2001;853-857.
87. Sameni M., Elliott E., Ziegler G., Fortgens P.H., Dennison C., Sloane B.F. Cathepsin B and D are localized at the surface of human breast cancer cells. Pathol. Oncol. Res. 1:1995;43-53.
88. Zajc I., Sever N., Bervar A., Lah T.T. Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett. 187:2002;185-190.
89. Scaddan P.B., Dufresne M.J. Characterization of cysteine proteases and their endogenous inhibitors in MCF-7 and adriamycin-resistant MCF-7 human breast cancer cells. Invasion Metastasis. 13:1995;301-313.
90. Lah T.T., Cercek M., Blejec A.et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin. Cancer Res. 6:2000;578-584.
91. Thomssen C., Schmitt M., Goretzki L.et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin. Cancer Res. 1:1995;741-746.
92. Lah T.T., Kos J., Blejec A.et al. The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol. Oncol. Res. 3:1997;89-99.
93. Foekens J.A., Kos J., Peters H.A.et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16:1998;1013-1021.
94. Budihna M., Skrk J., Zakotnik B., Gabrijelcic D., Lindtner J. Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur. J. Cancer. 5:1995;661-664.
95. Thomssen C., Oppelt P., Janicke F.et al. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res. 18:1998;2173-2180.
96. Harbeck N., Alt U., Berger U.et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin. Cancer Res. 7:2001;2757-2764.
97. Harbeck N., Alt U., Berger U.et al. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int. J. Biol. Markers. 15:2000;79-83.
98. Scorilas A., Fotiou S., Tsiambas E.et al. Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol. Chem. 383:2002;1297-1303.
99. Warwas M., Haczynska H., Gerber J., Nowak M. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur. J. Clin. Chem. Clin. Biochem. 35:1997;301-304.
100. Haczynska H., Warwas M., Gerber J., Nowak M. Aktywność katepsyny B w surowicy kobiet z nowotworami zlośćliwymi jajników: I. Czêœæ, Znaczenie diagnostyczne. Ginekol. Pol. (Suppl. 3):1994;1187-1191.
101. Nishida Y., Kohno K., Kawamata T., Morimitsu K., Kuwano M., Miyakawa I. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol. Oncol. 56:1995;357-361.
102. Kobayashi H., Mobuhiko N., Sugimura M., Shinohara H., Ohi H., Terao T. Increased cell-surface urokinase in advanced ovarian cancer. Jpn. J. Cancer. 84:1993;633-640.
103. Kobayashi H., Ohi H., Sugimura M., Shinohara H., Fujii T., Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 52:1992;3610-3614.
104. Gerber J., Nowak M., Haczyńska H., Warwas M. Aktywnoś ć katepsyny B w surowicy kobiet z nowotworami zlośliwymi jajników: II. Czêść, Znaczenie w monitorowaniu skutecznoœci chemioterapii. Ginekol. Pol. (Suppl. 3):1994;1192-1196.
105. Warwas M., Gerber J., Haczynska H., Lukasik-Lemanska K. Comparison of cathepsin-B-like activity and CA 125 assays use in ovarian cancer diagnosis. Ginekol. Pol. 71:2000;400-405.
106. Makarewicz R., Drewa G., Szymański W., Skonieczna-Makarewicz I. Cathepsin B in predicting the extent of the cervix carcinoma. Neoplasma. 42:1995;21-24.
107. Makarewicz R., Drewa G., Szymański W. Aktywność katepsyny B i D w surowicy krwi kobiet chorych na raka szyjki macicy. Ginekol. Pol. 65:1994;578-581.
108. Waghray A., Keppler D., Sloane B.F., Schuger L., Chen Y.Q. Analysis of a truncated form of cathepsin H in human prostate tumor cells. J. Biol. Chem. 277:2002;11533-11538.
109. Fernandez P.L., Farre X., Nadal A.et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer. 95:2001;51-55.
110. Friedrich B., Jung K., Lein M.et al. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur. J. Cancer. 35:1999;138-144.
111. Sinha A.A., Jamuar M., Wilson M.J., Rozhin J., Sloane B.F. Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. Prostate. 49:2001;172-184.
112. Colella R., Goodwyn E., Gopal P. Increased cell density decreases cysteine proteinase inhibitor activity and increases invasive ability of two prostate tumor cell lines. Cancer Lett. 185:2002;163-172.
113. Sinha A.A., Wilson M.J., Gleason D.F., Reddy P.K., Sameni M., Sloane B.F. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate. 26:1995;171-178.
114. Sinha A.A., Quast B.J., Wilson M.J.et al. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer. 94:2002;3141-3149.
115. Sinha A.A., Quast B.J., Wilson M.J.et al. Ratio of cahepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cacer. Prostate. 48:2001;274-284.
116. Sinha A.A., Quast B.J., Korkowski J.C.et al. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score. Anticancer Res. 19:1999;2821-2830.
117. Weiss R.E., Liu B.C.-S., Ahlering T., Dubeau L., Droller M.J. Mechanisms of human bladder tumor invasion: role of protease cathepsin B. J. Urol. 144:1990;798-804.
118. Akpolat I., Baris Y.S., Yilmaz A.F.et al. Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma. Neoplasma. 45:1998;365-368.
119. Redwood S.M., Liu B.C.-S., Weiss R.E., Hodge D.E., Droller M.J. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer. 69:1992;1212-1219.
120. Visscher D.W., Sloane B.F., Sameni M., Babiarz J.W., Jacobson J., Crissman J.D. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod. Pathol. 7:1994;76-81.
121. Eijan A.M., Casabe A.R., Puricelli L.et al. Levels of plasma cysteine-proteinase activity in bladder cancer patients. Oncol. Rep. 4:1997;447-450.
122. Eijan A.M., Sandes E., Puricelli L., Bal de Kier Joffe E., Casabe A.R. Cathepsin B levels in urine from bladder cancer patients. Oncol. Rep. 7:2000;1395-1399.
123. Staack A., Koenig F., Daniltchenko D.et al. Cathepsins, B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. Urology. 59:2002;308-312.
124. Sier C.F., Casetta G., Verheijen J.H.et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res. 6:2000;2333-2340.
125. Emmert-Buck M.R., Roth M., Zhuang Z.et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol. 145:1994;1285-1290.
126. Campo E., Munoz J., Miquel R.et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol. 145:1994;301-309.
127. Adenis A., Huet G., Zerimech F., Hecquet B., Balduyck M., Peyrat J.P. Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Cancer Lett. 96:1995;267-275.
128. Shuja S., Sheahan K., Murnane M.J. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int. J. Cancer. 49:1991;341-346.
129. Satoh Y., Higashi T., Nouso K.et al. Cathepsin B in the growth of colorectal cancer: increased activity of cathepsin B in human colorectal cancer. Acta Med. Okayama. 50:1996;305-311.
130. Kim K., Cai J., Shuja S., Kuo T., Murnane M.J. Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas. Int. J. Cancer. 79:1998;324-333.
131. Hazen L.G., Bleeker F.E., Lauritzen B.et al. Comparative localization of cathepsin B protein and activity in colorectal cancer. J. Histochem. Cytochem. 48:2000;1421-1430.
132. del Re E.C., Shuja S., Cai J., Murnane M.J. Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas. Br. J. Cancer. 82:2000;1317-1326.
133. Herszenyi L., Plebani M., Carraro P.et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 86:1999;1135-1142.
134. Schwartz G.K., Wang H., Lampen N., Altorki N., Kelsen D., Albino A.P. Defining the invasive phenotype of proximal gastric cancer cells. Cancer. 73:1994;22-27.
135. Russo A., Bazan V., Migliavacca M.et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin. Cancer Res. 6:2000;178-184.
136. Hirano T., Yoshioka H. Serum cathepsin B levels, urinary excretion of cathepsin B and tissue cathepsin B content in the patients with gastric cancer. Nippon Geka Hokan. 62:1993;217-221.
137. Herszenyi L., Plebani M., Carraro P.et al. Proteases in gastrointestinal neoplastic diseases. Clin. Chim. Acta. 291:2000;171-187.
138. Khan A., Krishna M., Baker S.P., Malhothra R., Banner B.F. Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch. Pathol. Lab. Med. 122:1998;172-177.
139. Ohta T., Terada T., Nagakawa T.et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br. J. Cancer. 69:1994;152-156.
140. Paciucci R., Berrozpe G., Tora M.et al. Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization. FEBS Lett. 385:1996;72-76.
141. Terada T., Ohta T., Minato H., Nakanuma Y. Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum. Pathol. 26:1995;746-752.
142. Niewczas M., Paczek L., Krawczyk M., Pawlak J., Bartlomiejczyk I., Gornicka B. Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma. Pol. Arch. Med. Wewn. 108:2002;653-662.
143. Farinati F., Herszenyi L., Plebani M.et al. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. Carcinogenesis. 17:1996;2581-2587.
144. Werle B., Ebert W., Klein W., Spiess E. Cathepsin B in tumors, normal tissue and isolated cells from the human lung. Anticancer Res. 14:1994;1169-1176.
145. Ebert W., Knoch H., Werle B., Trefz G., Muley Th., Spiess E. Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res. 14:1994;895-900.
146. Krepela E., Kasafirek E., Novak K., Viklicky J. Increased cathepsin B activity in human lung tumors. Neoplasma. 37:1990;61-70.
147. Werle B., Ebert W., Klein W., Spiess E. Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. Biol. Chem. Hoppe-Seyler. 376:1995;157-164.
148. Ledakis P., Tester W.T., Rosenberg N., Romero-Fischmann D., Daskal I., Lah T.T. Cathepsins B, D, and L in malignant human lung tissue. Clin. Cancer Res. 2:1996;561-568.
149. Krepela E., Prochazka J., Karova B., Cermak J., Roubkova H. Cathepsin B, thiols and cysteine protease inhibitors in squamous-cell lung cancer. Neoplasma. 44:1997;219-239.
150. Schweiger A., Staib A., Werle B.et al. Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking. Br. J. Cancer. 82:2000;782-788.
151. Kos J., Sekirnik A., Kopitar G.et al. Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br. J. Cancer. 85:2001;1193-1200.
152. Inoue T., Ishida T., Sugio K., Sugimachi K. Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res. 54:1994;6133-6136.
153. Sukoh N., Abe S., Nakajima I.et al. Immunohistochemical distributions of cathepsin B and basement membrane antigens in human lung adenocarcinoma: association with invasion and metastasis. Virchows Archiv. 424:1994;33-38.
154. Sukoh N., Abe S., Ogura S.et al. Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer. 74:1994;46-51.
155. Ozeki Y., Takishima K., Takagi K.et al. Immunohistochemical analysis of cathepsin B expression in human lung adenocarcinoma: the role in cancer progression. Jpn. J. Cancer Res. 84:1993;972-975.
156. Knoch H., Werle B., Ebert W., Spiess E. Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer. Int. J. Oncol. 5:1994;77-85.
157. Mori M., Kohli A., Baker S.P., Savas L., Fraire A.E. Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful? Mod. Pathol. 10:1997;572-577.
158. Werle B., Julke B., Lah T.T., Kos J., Spiess E., Ebert W. Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. Br. J. Cancer. 75:1997;1137-1143.
159. Sivaparvathi M., Sawaya R., Gokaslan Z.L., Chintala S.K., Rao J.S., Chintala K.S. Expression and the role of cathepsin H in human glioma progression and invasion. Cancer Lett. 104:1996;121-126.
160. Sivaparvathi M., Sawaya R., Wang S.W.et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin. Exp. Metastasis. 13:1995;49-56.
161. Sivaparvathi M., Yamamoto M., Nicolson G.L.et al. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin. Exp. Metastasis. 1:1996;27-34.
162. Mikkelsen T., Yan P.S., Ho K.L., Sameni M., Sloane B.F., Rosenblum M.L. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J. Neurosurg. 83:1995;285-290.
163. Rempel S.A., Rosenblum M.L., Mikkelsen T.et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54:1994;6027-6031.
164. Demchik L.L., Sameni M., Nelson K., Mikkelsen T., Sloane B.F. Cathepsin B and glioma invasion. Int. J. Dev. Neurosci. 17:1999;483-494.
165. Berquin I.M., Sloane B.F. Intracellular protein catabolism. vol. 35:1996;281-294 Plenum, London.
166. Muntener K., Zwicky R., Csucs G., Baici A. The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells. Histochem. Cell Biol. 119:2003;93-101.
167. Strojnik T., Zidanik B., Kos J., Lah T.T. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery. 48:2001;598-605.
168. Strojnik T., Kos J., Zidanik B., Golouh R., Lah T.T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res. 5:1999;559-567.
169. Strojan P., Budihna M., Smid L.et al. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 6:2000;1052-1062.
170. Budihna M., Strojan P., Smid L.et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe-Seyler. 377:1996;385-390.
171. Kos J., Smid A., Krasovec M.et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe-Seyler. 376:1995;401-405.
172. Russo A., Bazan V., Gebbia N.et al. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Cancer (Phila.). 76:1995;1757-1764.
173. Smid L., Strojan P., Budihna M.et al. Prognostic value of cathepsins B, L and stefins A and B in laryngeal carcinoma. Eur. Arch. Otorhinolaryngol.
174. Strojan P., Budihna M., Smid L., Svetic B., Vrhovec I., Skrk J. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma. 48:2001;66-71.
175. Strojan P., Budihna M., Smid L.et al. Cathepsin H in squamous cell carcinoma of the head and neck. Radiol. Oncol. 33:1999;143-151.
176. Nikitakis N.G., Rivera H., Lopes M.A.et al. Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. Am. J. Clin. Pathol. 119:2003;574-586.
177. Qian F., Chan S.-J., Achkar Ch., Steiner D.F., Frankfater A. Transcriptional regulation of cathepsin B expression in B16 melanomas of varying metastatic potential. Biochem. Biophys. Res. Commun. 202:1994;429-436.
178. Yoshii A., Kageshita T., Tsushima H., Ono T. Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours. Arch. Dermatol. Res. 287:1995;209-213.
179. Sloane B.F., Rozhin J., Robinson D., Honn K.V. Role for cathepsin B and cystatins in tumor growth and progression. Biol. Chem. Hoppe-Seyler. 371:1990;193-198. [Suppl.].
180. Frohlich E., Schlagenhauff B., Mohrle M., Weber E., Klessen C., Rassner G. Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer. 91:2001;972-982.
181. Kageshita T., Yoshii A., Kimura T.et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. Arch. Dermatol. Res. 287:1995;266-272.
182. Kos J., Stabuc B., Schweiger A.et al. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin. Cancer Res. 3:1997;1815-1822.
183. Kirschke H., Clausen T., Gohring B.et al. Concentrations of lysosomal cysteine proteases are decreased in renal cell carcinoma compared with normal kidney. J. Cancer Res. Clin. Oncol. 123:1997;402-406.
184. Castren J.P., Kamel D.E., Nurmi M.J., Collan Y.U. Cathepsin H expression distinguishes oncocytomas from renal cell carcinomas. Anticancer Res. 20:2000;537-540.
185. Nasu K., Kai K., Fujisawa K., Takai N., Nishida Y., Miyakawa I. Expression of cathepsin L in normal endometrium and endometrial cancer. Eur. J. Obstet. Gynaecol. Reprod. Biol. 99:2001;102-105.
186. Shuja S., Cai J., Iacobuzio-Donahue C.et al. Cathepsin B activity and protein levels in thyroid carcinoma. Graves' disease, and multinodular goiters. Thyroid. 9:1999;569-577.
187. Wurl P., Taubert H., Meye A.et al. Immunohistochemical and clinical evaluation of cathepsin expression in soft tissue sarcomas. Virchows Arch. 430:1997;221-225.
188. Soderstrom M., Ekfors T., Bohling T., Aho A., Aro H.T., Vuorio E. Cysteine proteinases in chondrosarcomas. Matrix Biol. 19:2001;717-725.
189. Nagai A., Terashima M., Harada T.et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin. Chim. Acta. 329:2003;53-60.
190. Fujita Y., Nakata K., Yasui N.et al. Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization. J. Clin. Endocrinol. Metab. 85:2000;425-431.
191. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 273:1996;1236-1238.
192. Hou W.S., Bromme D., Zhao Y.et al. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J. Clin. Invest. 103:1999;731-738.
193. Li Z., Hou W.S., Escalante-Torres C.R., Gelb B.D., Bromme D. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J. Biol. Chem. 277:2002;28669-28676.
194. Kiviranta R., Morko J., Uusitalo H., Aro H.T., Vuorio E., Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16:2001;1444-1452.
195. Sukhova G.K., Shi G.P., Simon D.I., Chapman H.A., Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102:1998;576-583.
196. Sukhova G.K., Zhang Y., Pan J.H.et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 111:2003;897-906.
197. Han S.-R., Momeni A., Strach K.et al. Enzymatically modified LDL induces cathepsin H in human monocytes. Potential relevance in early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 23:2003;661-667.
198. Kumamoto T., Ueyama H., Sugihara R., Kominami E., Goll D.E., Tsuda T. Calpain and cathepsins in the skeletal muscle of inflammatory myopathies. Eur. Neurol. 37:1997;176-181.
199. Gallardo E., de Andres I., Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J. Neuropathol. Exp. Neurol. 60:2001;847-855.
200. Kumamoto T., Yukishige K., Ito T.et al. Cellular distribution of proteolytic enzymes in the skeletal muscle of sarcoid myopathy. Acta Neuropathol. (Berl). 104:2002;38-44.
201. Bernstein H.G., Kirschke H., Wiederanders B., Pollak K.H., Zipress A., Rinne A. The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: a review. Mol. Chem. Neuropathol. 27:1996;225-247.
202. Ii K., Ito H., Kominami E., Hirano A. Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch., A Pathol. Anat. Histopathol. 423:1993;185-194.
203. Beck H., Schwarz G., Schroter C.J.et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur. J. Immunol. 31:2001;3726-3736.
204. Baker C.A., Martin D., Manuelidis L. Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles. J. Virol. 76:2002;10905-10913.
205. Nagai A., Murakawa Y., Terashima M.et al. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology. 55:2000;1828-1832.
206. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J. Rheumatol. 26:1999;717-719.
207. Hansen T., Petrow P.K., Gaumann A.et al. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. J. Rheumatol. 27:2000;859-865.
208. Biroc S.L., Gay S., Hummel K.et al. Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis Rheum. 44:2001;703-711.
209. Baici A., Lang A., Horler D., Kissling R., Merlin C. Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann. Rheum. Dis. 54:1995;289-297.
210. Baici A., Horler D., Lang A., Merlin C., Kissling R. Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. Ann. Rheum. Dis. 54:1995;281-288.
211. Berardi S., Lang A., Kostoulas G., Horler D., Vilei E.M., Baici A. Alternative messenger RNA splicing and enzyme forms of cathepsin B in human osteoarthritic cartilage and cultured chondrocytes. Arthritis Rheum. 44:2001;1819-1831.
212. Lang A., Horler D., Baici A. The relative importance of cysteine peptidases in osteoarthritis. J. Rheumatol. 27:2000;1970-1979.
213. Mantle D., Falkous G., Walker D. Quantification of protease activities in synovial fluid from rheumatoid and osteoarthritis cases: comparison with antioxidant and free radical damage markers. Clin. Chim. Acta. 284:1999;45-58.
214. Ikeda Y., Ikata T., Mishiro T., Nakano S., Ikebe M., Yasuoka S. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J. Med. Invest. 47:2000;61-75.
215. Hashimoto Y., Kakegawa H., Narita Y.et al. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem. Biophys. Res. Commun. 283:2001;334-339.
216. Keyszer G., Redlich A., Haupl T.et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthritis Rheum. 41:1998;1378-1387.
217. Hou W.S., Li W., Keyszer G. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 46:2002;663-674.
218. Hou W.S., Li Z., Gordon R.E.et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol. 159:2001;2167-2177.
219. Konttinen Y.T., Mandelin J., Li T.F.et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 46:2002;953-960.
220. Eley B.M., Cox S.W. Advances in periodontal diagnosis 7. Proteolytic and hydrolytic enzymes link with periodontitis. Br. Dent. J. 184:1998;323-328.
221. Ichimaru E., Tanoue M., Tani M.et al. Cathepsin B in gingival crevicular fluid of adult periodontitis patients: identification by immunological and enzymological methods. Inflamm. Res. 45:1996;277-282.
222. Eley B.M., Cox S.W. The relationship between gingival crevicular fluid cathepsin B activity and periodontal attachment loss in chronic periodontitis patients: a 2-year longitudinal study. J. Periodontal. Res. 31:1996;381-392.
223. Zheng T., Zhu Z., Wang Z.et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J. Clin. Invest. 106:2000;1081-1093.
224. Stypmann J., Glaser K., Roth W.et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl. Acad. Sci. U. S. A. 99:2002;6234-6239.
225. Kawada A., Hara K., Kominami E., Hiruma M., Noguchi H., Ishibashi A. Processing of cathepsins L, B and D in psoriatic epidermis. Arch. Dermatol. Res. 289:1997;87-93.
226. Moran M.T., Schofield J.P., Hayman A.R., Shi G.P., Young E., Cox T.M. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 96:2000;1969-1978.
227. Cimerman N., Brguljan P.M., Krasovec M., Suskovic S., Kos J. Serum concentration and circadian profiles of cathepsins B, H and L, and their inhibitors, stefins A and B, in asthma. Clin. Chim. Acta. 310:2001;113-122.
228. Steinfeld S., Maho A., Chaboteaux C.et al. Prolactin up-regulates cathepsin B and D expression in minor salivary glands of patients with Sjogren's syndrome. Lab. Invest. 80:2000;1711-1720.
229. Cimerman N., Brguljan P.M., Krasovec M., Suskovic S., Kos J. Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera. Clin. Chim. Acta. 282:1999;211-218.
230. Zore I., Krasovec M., Cimerman N.et al. Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol. Chem. 382:2001;805-810.
231. Mort JS, (chapter 209), Kirschke H, (chapters: 210, 211, 213), Bromme D, (chapter 212), Turk B, Dolenc I, Turk V, (chapter 214). In: Barrett AJ, Rawlings ND, Woessner JF, editors. Handbook of Proeolytic Enzymes. Academic Press, 1998.
232. Barrett AJ, Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB) Enzyme Nomenclature. Recommendations Peptidase Nomenclature, http://www.chem.qmw.ac.uk/iubmb/enzyme/ EC34/.
233. Turk V, Bode W. (chapter 9: 161-178). In: Avilės FX, editor. Innovations in Proteases and their Inhibitors. Berlin: Walter de Gruyter and Co.; 1993.
234. Velasco G., Ferrando A.A., Puente X.S., Sánchez L.M., López-Otín C. Human cathepsin O: molecular cloning from a breast carcinoma, production of the active enzyme in Escherichia coli, and expression analysis in human tissues. J. Biol. Chem. 269:1994;27136-27142.
235. Wang B., Shi G.P., Yao P.M., Li Z., Chapman H.A., Brömme D. Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization. J. Biol. Chem. 273:1998;32000-32008.
236. Santamaría I., Velasco G., Pendás A.M., Fueyo A., López-Otín C. Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location. J. Biol. Chem. 273:1998;16816-16823.
237. Nägler D.K., Ménard R. Human cathepsin X: a novel cysteine protease of the papain family with a very short proregion and unique insertions. FEBS Lett. 434:1998;135-139.
238. Rao N.V., Rao G.V., Hoidal R.J. Human dipeptidyl-peptidase: I. Gene characterization, localization, and expression. J. Biol. Chem. 272:1997;10260-10265.
239. Shi G.-P., Webb A.C., Foster K.E.et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J. Biol. Chem. 269:1994;11530-11536.
240. Drake F.H., Dodds R.A., James I.E.et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271:1996;12511-12516.
241. LaLonde J.M., Zhao B., Janson C.A.et al. The crystal structure of human procathepsin K. Biochemistry. 38:1999;862-869.
242. Punturieri A., Filippov S., Allen E.et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J. Exp. Med. 192:2000;789-800.
243. Buhling F., Gerber A., Hackel C.et al. Expression of cathepsin K in lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 20:1999;612-619.
244. Buhling F., Waldburg N., Gerber A.et al. Cathepsin K expression in human lung. Adv. Exp. Med. Biol. 477:2000;281-286.
245. Haeckel C., Krueger S., Buehling F.et al. Expression of cathepsin K in the human embryo and fetus. Dev. Dyn. 216:1999;89-95.
246. Adachi W., Kawamoto S., Ohno I.et al. Isolation and characterization of human cathepsin V: a major proteinase in corneal epithelium. Invest Ophthalmol. Vis. Sci. 39:1998;1789-1796.
247. + T-lymphocytes. FEBS Lett. 405:1997;253-259.
248. Brown J., Matutes E., Singleton A.et al. Lymphopain, a cytotoxic T and natural killer cell-associated cysteine proteinase. Leukemia. 12:1998;1771-1781.